The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate

Launched by BEIJING CHAO YANG HOSPITAL · May 22, 2024

Keywords

ClinConnect Summary

Patients undergoing spinal anesthesia were received remimazolam besylate for sedation continuously. Both the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) and the Wavelet index (WLi) were used to monitor the depth of anesthesia of remimazolam, and exploring the correlation and consistency between MOAA/S score and WLi value at the same time.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ASA was classified as I-III
• • The operation time was less than 120 minutes
• • Informed consent is signed by all study participants
• • Elective lower extremity surgery under spinal anesthesia was performed
• Exclusion Criteria:
• • Pregnant or lactating women
• • Patients with Difficult Airways
• • History of severe neurological and muscular diseases and mental retardation
• • Patients with severe respiratory and circulatory diseases, including acute heart failure. Unstable angina pectoris. Resting ECG heart rate \<50 beats/min. QTc: ≥470ms in men and ≥480ms in women. Third degree atrioventricular block. Severe arrhythmia. Moderate to severe heart valve disease. Chronic obstructive pulmonary disease. A history of severe asthma.
• • Abnormal liver and kidney function: ALT and/or AST exceeding 2.5 times the upper limit of the medical reference range
• • Take diazole drugs and/or opioids in one month or nearly three months
• • Patients who were allergic to or contraindicated to benzodiazepines, opioids, propofol, flumazenil, naloxone, etc
• • Patients who could not monitor the depth of anesthesia for various reasons